The present invention relates to a method for determining a subject s resistance to treatment with 2 2 dimethyl N ((S) 6 oxo 6 7 dihydro 5H dibenzo[b d]azepin 7 yl) N(2 2 3 3 3 pentafluoro propyl) malonamide by measuring the levels a biomarker or biomarkers present in a biological sample obtained from the subject the biomarker being IL6 and/or IL8. The present invention also relates to a combination therapy for a patient suffering from a proliferative disorder comprising administering to the patient 2 2 Dimethyl N ((S) 6 oxo 6 7 dihydro 5H dibenzo[b d]azepin 7 yl) N(2 2 3 3 3 pentafluoro propyl) malonamide and an anti IL6 and/or an anti IL8 agent.
